Transcell Biologics secures funding from IAN Group and Quantiphi Inc. to advance Animal-Free Testing Solutions
Transcell Biologics, a pioneering biotech company at the forefront of translating adult stem cell technology into real-world applications, has announced a strategic investment from award-winning AI-first engineers, Quantiphi Inc, based in Boston. This investment aims to support expanding the client base and implementation of Digital Animal Replacement Technology (DART) as an Enterprise Solution for the global bio and pharmaceutical industry.
DART embodies an innovative leap forward in animal-free testing methods, fusing human MicroPhysiological Systems (hMPS) technology with AI/ML embedded in silico platform configurations to streamline and automate the bioassay processes producing statistically compliant reports. This innovative solution is designed to effectively test safety and efficacy concerns surrounding drugs and vaccines meant for human consumption.
The participation of the IAN Group in this strategic round underscores its commitment to supporting visionary entrepreneurs and investing in innovative startups that solve real-world problems through technology. Guided by a 2030 vision, IAN’s investment philosophy is centered on a risk-mitigated, high-return strategy, leveraging the Group’s extensive mentor network and global connections to breed startups driven by founders who excel in execution and are focused on addressing large market needs. IAN Group is dedicated to fostering growth in startups like Transcell Biologics, which are poised to revolutionize their sectors.
Dr. Subhadra Dravida, the Founder and CEO of Transcell Biologics, expressed that “DART represents a significant breakthrough in revolutionizing drug and vaccine testing. This innovative approach offers a decentralized strategy without additional infrastructure requirements at end users’ premises, enhancing the operating efficiency and accessibility of such validated testing procedures from their workstations.”
Mr Uday Chatterjee, Director, of Transcell Biologics shared that “the strategic participation of Quantiphi underscores their strong belief in the technology’s potential impact on society. He stated that Quantiphi’s commitment and support will accelerate the growth of DART across life science enterprises across the globe.”
The implementation of DART has gained significant traction in Indian markets, with leading biopharmaceutical companies already adopting this Enterprise Solution in their high-impact programs. Moreover, with the U.S. FDA Modernization Act 2.0 phasing out animal-based testing in drug discovery and development, Transcell Biologics is poised to expand its client base in the USA, Europe, and Japan through its collaboration with Quantiphi.
Transcell Biologics is poised toward its mission of revolutionizing animal-free testing in the biopharmaceutical industry and firmly supporting the 3Rs mandate for animal testing.
IAN Group
IAN Group is the country’s single largest platform for seed and early-stage investment platform with IAN Angel Network, BioAngels and IAN Fund I and IAN Alpha Fund enabling entrepreneurs to raise from Rs. 50 lakhs to Rs. 50 crores. The platform brings money, mentoring from successful entrepreneurs and global market access. The platform is sector-agnostic and has funded innovative start-ups across 19 sectors in India and 7 other countries, thereby growing the global footprint of companies. IAN has been listed by Forbes as one of iconic business and economic events of Independent India, over 75 years along with LIC, NASSCOM, RBI, Naukri.com amongst others.
About Transcell:
Transcell headquartered in Hyderabad, India is a leading innovation-driven once-in-generation biotech entity developing a portfolio of best-in-class productized offerings by applying their in-house hypothesis-based biobox platform technology. In Transcell’s universe, the productized offerings (applications) are broadly two types: Therapeutics and Non-Therapeutics. The flagship biosamples repository mediates a compelling journey with the noble purpose of finding answers to some of the globe’s most urgent complex medical needs.
About Quantiphi:
Quantiphi is an award-winning AI-first digital engineering company driven by the desire to reimagine and realize transformational opportunities at the heart of business. Since its inception in 2013, Quantiphi has solved the toughest and most complex business problems by combining deep industry experience, disciplined cloud and data engineering practices, and cutting-edge artificial intelligence research to achieve accelerated and quantifiable business results.